Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Tumour-specific mutations are ideal targets for cancer immunotherapy as they lack expression in healthy tissues and can potentially be recognized as neo-antigens by the mature T-cell repertoire. Their systematic targeting by vaccine approaches, however, has been hampered by the fact that every patient's tumour possesses a unique set of mutations ('the mutanome') that must first be identified. Recently, we proposed a personalized immunotherapy approach to target the full spectrum of a patient's individual tumour-specific mutations. Here we show in three independent murine tumour models that a considerable fraction of non-synonymous cancer mutations is immunogenic and that, unexpectedly, the majority of the immunogenic mutanome is recognized by CD4(+) T cells. Vaccination with such CD4(+) immunogenic mutations confers strong antitumour activity. Encouraged by these findings, we established a process by which mutations identified by exome sequencing could be selected as vaccine targets solely through bioinformatic prioritization on the basis of their expression levels and major histocompatibility complex (MHC) class II-binding capacity for rapid production as synthetic poly-neo-epitope messenger RNA vaccines. We show that vaccination with such polytope mRNA vaccines induces potent tumour control and complete rejection of established aggressively growing tumours in mice. Moreover, we demonstrate that CD4(+) T cell neo-epitope vaccination reshapes the tumour microenvironment and induces cytotoxic T lymphocyte responses against an independent immunodominant antigen in mice, indicating orchestration of antigen spread. Finally, we demonstrate an abundance of mutations predicted to bind to MHC class II in human cancers as well by employing the same predictive algorithm on corresponding human cancer types. Thus, the tailored immunotherapy approach introduced here may be regarded as a universally applicable blueprint for comprehensive exploitation of the substantial neo-epitope target repertoire of cancers, enabling the effective targeting of every patient's tumour with vaccines produced 'just in time'.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, peptide-based immunotherapeutics often tend to induce primarily CD4+ T-cell responses [36].”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These mutated epitopes of Pbk and Actn4 were recognized and reacted to by CD8+ or CD4+ T cells, respectively, upon RNA monotope vaccinations and showed good MHC class I binding scores (‘low score’ 0.1 and 0.2, respectively) (25).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“Additional neoatigens formulated in the mRNA vaccine may help improve the anti-tumor response of mRNA vaccines using neoantigens, such as demonstrated by Kreiter et al. (25).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [25]
In the citing paper
“Interestingly, we also observed an elevated percentage of ChAT–GFP+ cells among CD4+ T cells carrying natural TCRs (TCR Vβ5–) (Fig. 4j,k), suggesting that ChAT expression in T cells can also be induced through ‘antigen spreading’35.”
From Tumor-specific cholinergic CD4+ T lymphocytes guide immunosurveillance of hepatocellular carcinoma (2023) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615
Self-citationCheckpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Adaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,436
Cited by
Items 901–1,000 of 1,001
Movahed, Z. G., Sharif, E., Ahmadzadeh, M., Nezafat, N., Jahandar, H., & Mohit, E. (2022) · Molecular Biology Reports · doi:10.1007/s11033-021-06727-w · Cited by 8
“A considerable number of somatic mutations are presented in human tumors [5].”
BackgroundCarter, J. A., Matta, B., Battaglia, J., Somerville, C. C., Harris, B. D., LaPan, M., Atwal, G. S., & Barnes, B. J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007935 · Cited by 8
“Those genes above a given threshold and that are expressed in 1% of tumor samples at a threshold of 5 normalized read counts were said to have CT expression.”
BackgroundImmunoNodes – graphical development of complex immunoinformatics workflows
Schubert, B., de la Garza, L., Mohr, C., Walzer, M., & Kohlbacher, O. (2017) · BMC Bioinformatics · doi:10.1186/s12859-017-1667-z · Cited by 9
“Their applications span a wide variety ranging from basic immunological to translational research, especially in the field of cancer research [1 – 3].”
BackgroundAn Ultrastable Virus‐Like Particle with a Carbon Dot Core and Expanded Sequence Plasticity
Zhang, W., Jia, Q., Teng, Y., Yang, M., Zhang, H., Zhang, X., Wang, P., Ge, J., Cao, S., & Li, F. (2021) · Small · doi:10.1002/smll.202101717 · Cited by 8
Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer
Aderonke, A. B., Ibrahim, R. B., & Huang, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184624 · Cited by 9
“A recent study reported the stimulatory effect of a peptide neoantigens vaccine on CD4+ rather than on CD8+ T cell responses [326,327].”
BackgroundSun, J., Bai, H., Wang, Z., Duan, J., Li, J., Guo, R., & Wang, J. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13322 · Cited by 8
Translate less, prime better, to improve anti-tumor responses
Burbage, M., Gros, M., & Amigorena, S. (2019) · Nature Immunology · doi:10.1038/s41590-019-0371-8 · Cited by 8
Harnessing Computational Strategies to Overcome Challenges in mRNA Vaccines
Zhao, S., Chen, J., Dai, T., Li, G., Huang, L., Xin, J., Zhang, Y., Chen, Y., He, X., Huang, H., et al. (2025) · Physiology · doi:10.1152/physiol.00047.2024 · Cited by 8
Li, F., Wang, D., Gao, Y., & Cui, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1648698 · Cited by 7
Edwards, J. M., Senthi, S., Smith, R., Burridge, H., Owens, C., Shackleton, M. J., Andrews, M. C., & van Zelm, M. C. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012317 · Cited by 7
Shen, X., Fan, S., He, J., Luo, L., Li, J., Wu, C., Yang, K. S., Xia, X., & Kuai, R. (2025) · Advanced Science · doi:10.1002/advs.202512139 · Cited by 7
Tumorvakzinierung –Strategien und Timing
Maringer, Y., & Walz, J. S. (2021) · Der Internist · doi:10.1007/s00108-021-01138-2 · Cited by 7
Salomon, N., Helm, A., Selmi, A., Fournier, C., Diken, M., Schrörs, B., Scholz, M., Kreiter, S., Durante, M., & Vascotto, F. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.12.042 · Cited by 8
Self-citationIn vivo assembly of epitope-coated biopolymer particles that induce anti-tumor responses
Jenika, D., Pounraj, S., Wibowo, D., Flaxl, L. M., Rehm, B. H. A., & Mintern, J. D. (2024) · npj Vaccines · doi:10.1038/s41541-023-00787-8 · Cited by 8
“Accordingly, engineering MHC II epitopes into vaccine platforms is considered an effective strategy to boost vaccine induced CTL responses 25 , however in this case immunisation with BP-OVA 257-264 alone elicited a CTL response similar in magnitude, indicating in this setting inclusion of an…”
BackgroundMelanoma neoantigen vaccines: Are we getting more personal now?
Latifyan, S., & Haanen, J. B. A. G. (2024) · Med · doi:10.1016/j.medj.2024.03.004 · Cited by 10
Harnessing microbial antigens as cancer antigens: a promising avenue for cancer immunotherapy
Zhang, T., Zhang, X., Chen, J., Zhang, X., & Zhang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1411490 · Cited by 10
“For example, a recently identi fi ed melanoma epitope has been recognized by CD4 + T cells, with a neoantigen vaccine predominantly activating this subset of immune cells (12, 13).”
BackgroundSanterre, J. P., Yang, Y., Du, Z., Wang, W., & Zhang, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1492323 · Cited by 7
New Immunotherapies in Oncology Treatment and Their Side Effect Profiles
Sriratana, P., & Norton, J. A. (2018) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2018.04.170387 · Cited by 8
Immuno-oncology in triple-negative breast cancer
Heimes, A.-S., & Schmidt, M. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2020.124 · Cited by 7
“While the focus of anti-tumor immunity research has long been on MHC I and CD8 T cells, it could be shown in mouse models that the majority of immunogenic mutations are presented via MHC II and recognized by CD4 T cells([56]).”
BackgroundLi, D., Ma, D., & Hou, Y. (2023) · Infectious Agents and Cancer · doi:10.1186/s13027-023-00507-w · Cited by 8
“Alspach E, Lussier DM, Miceli AP, Kizhvatov I, DuPage M, Luoma AM, et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy.”
BackgroundInfluentialMa, S., Veld, R. V. H. I. ‘., Hao, Y., Gu, Z., Rich, C. C., Gelmi, M. C., Mulder, A. A., van Veelen, P. A., Vu, T. H. K., van Hall, T., et al. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.1.42 · Cited by 7
Chen, T., Hu, R., Wan, Y., Sun, F., Wang, Z., Yue, J., Chen, J., Han, G., Wei, G., & Dong, Z. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.02.132 · Cited by 7
Integrating immunotherapy in the (neo)adjuvant setting of early breast cancer
Chan, J. J., Tan, T. J., & Dent, R. A. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000675 · Cited by 8
Adoptive tumor infiltrating lymphocyte transfer as personalized immunotherapy
Díaz-Cano, I., Paz-Ares, L. G., & Otano, I. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.003 · Cited by 8
Vrecko, S., Guenat, D., Mercier‐Letondal, P., Faucheu, H., Dosset, M., Royer, B., Galaine, J., Boidot, R., Kim, S. C. H., Jary, M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26247 · Cited by 7
“Interestingly, most of the specific-neoantigen immune responses observed are mediated by CD4+ T cells [21] and several studies highlighted a critical role for neoantigen-specific CD4+ T cell responses in tumor elimination [21–23].”
BackgroundA Conceptual Framework for Inducing T Cell-Mediated Immunity Against Glioblastoma
Marx, S., Godicelj, A., & Wucherpfennig, K. W. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00945-5 · Cited by 7
“Also, it will be important to compare peptide-based approaches to mRNA-based technologies because this platform may enable more rapid formulation of personalized vaccines [63], an aspect that is relevant in aggressive tumor types such as glioblastoma.”
BackgroundRNA Vaccination Therapy: Advances in an Emerging Field
Kreiter, S., Diken, M., Pascolo, S., Nair, S. K., Thielemans, K., & Geall, A. J. (2016) · Journal of Immunology Research · doi:10.1155/2016/9703914 · Cited by 7
Self-citationWijfjes, Z., Ramos‐Tomillero, I., Gall, C. M. L., van Dinther, E. A. W., Turlings, F., Classens, R., Manna, S., van Dalen, D., Peters, R. J. R. W., Schouren, K., et al. (2025) · RSC Chemical Biology · doi:10.1039/d5cb00014a · Cited by 7
“65,66 67–69 Dosing and specific targeting is particularly important for CD4-epitope delivery, as too high doses could suppress tumor immunity via antigen-specific killing of cDC1s by cytotoxic Tr1 CD4 + T cells.”
ZHANG, Y., Xiong, S., Zheng, W., Liu, J., Zhao, Y., Lv, J., Zhang, Y., Guo, L., & Liang, T. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117858 · Cited by 7
Wu, P., Ge, J., Hou, X., Qu, H., Ouyang, J., Wang, D., Tong, T., Meng, Y., Yan, Q., Shi, L., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218459 · Cited by 6
Li, Z., Zhang, F., Luyu, H., Wenqiang, Z., Ismail, M., & Rueckert, J.-C. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103125 · Cited by 6
Li, Z., Zhang, H., & Wang, R. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124364 · Cited by 8
CD4 + T cells impair tumor growth through IL-3 and TNF-dependent vascular damage
Lian, Q., Nie, J., Singh, J., Chen, Q., Matta, J. L., Chan, W., Balmaceno-Criss, M., Vacchio, M. S., Yu, W., Clark, A. D., et al. (2026) · Science · doi:10.1126/science.ads7910 · Cited by 7
Elliot, T. A. E., Lecky, D. A. J., & Bending, D. (2023) · Essays in Biochemistry · doi:10.1042/ebc20220247 · Cited by 8
RNA-based therapies in hepatocellular carcinoma: state of the art and clinical perspectives
Xing, L., Wang, Z., Li, D., Li, J., & Liu, M. (2024) · Hepatoma Research · doi:10.20517/2394-5079.2024.25 · Cited by 11
Arrizabalaga, L., Trani, C. A. D., Fernández-Sendin, M., Bella, Á., Russo-Cabrera, J. S., Gomar, C., Ardaiz, N., Belsúe, V., González-Gomariz, J., Zalba, S., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03196-2 · Cited by 6
A modular vaccine platform for optimized lipid nanoparticle mRNA immunogenicity
Fang, Z., Monteiro, V. S., Oh, C., Janabi, K. A., Romero, L., Ahsan, N., Yang, L., Peng, L., DiMaio, D., Lucas, C. G. D. O., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01478-6 · Cited by 7
“Additionally, a recent study indicated that synthetic peptides of 27-base polymer/oligonucleotide neoepitopes from B16F10 tumour cells were more likely to trigger T cell responses than mRNAs encoding the same neoantigens 16 , possibly due to a lack of translocation of the mRNAs.”
Messenger RNA and Plasmid DNA Vaccines for the Treatment of Cancer
Moseman, J. E., Shim, D., Jeon, D., Rastogi, I., Schneider, K. M., & McNeel, D. G. (2025) · Vaccines · doi:10.3390/vaccines13090976 · Cited by 7
“In the case of mRNA cancer vaccines, there have been reports of strong cell-mediated immunity, characterized by the generation of CD4+ and CD8+ antigen-specific immune responses [45–48].”
Towards customized cancer vaccines: a promising filed in personalized cancer medicine
Xu, X., Zhou, Z., Li, H., & Fan, Y. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1909479 · Cited by 6
Reedy, M. B., Jonnalagadda, S., & Palle, K. (2021) · Pathology & Oncology Research · doi:10.3389/pore.2021.1609922 · Cited by 6
“Some of the important changes include the upregulation of tumor cell’s MHC class 1 and 2 antigens and death receptors such as Fas/ CD95 [11].”
BackgroundPrecision immunointerception of EGFR-driven tumorigenesis for lung cancer prevention
Pan, J., Xiong, D., Zhang, Q., Palen, K. A., Shoemaker, R. H., Johnson, B. D., Sei, S., Wang, Y., & You, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1036563 · Cited by 8
“Advanced NSCLC patients harboring mutations in the EGFR gene show initially good responses to TKIs but ultimately relapse (6).”
BackgroundSmart Cancer Nanomedicine for Synergetic Therapy
Kanungo, A., Mohanty, C., & Acharya, S. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673300897240602130258 · Cited by 6
Dagotto, G., Colarusso, A., Patio, R. C., Li, D., Anioke, T., Giffin, V. M., Guan, R., Anand, T., Mbiwan, E. R., Aïd, M., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009644 · Cited by 6
“Before each tumor experiment, cells were thawed and passaged two times to expand before the challenge.”
What do cancer-specific T cells ‘see’?
Shah, S., Al‐Omari, A., Cook, K., Paston, S. J., Durrant, L. G., & Brentville, V. A. (2022) · Discovery Immunology · doi:10.1093/discim/kyac011 · Cited by 7
“Finally, the most common form of neoepitope is the ignored neoepitopes that do not induce relevant immune responses alone but that can drive immunity when primed in the context of vaccines [29, 77].”
BackgroundMethodPascolo, S. (2023) · European Journal of Immunology · doi:10.1002/eji.202249941 · Cited by 6
Identification of immunogenic mutant neoantigens in the genome of murine melanoma
Kosorukov, V. S., Baryshnikova, M. A., Kosobokova, E. N., Yakovishina, D. Y., Ershova, A. S., & Pekov, Y. A. (2019) · Russian Journal of Biotherapy · doi:10.17650/1726-9784-2019-18-3-23-30 · Cited by 6
Fundamentals of Cancer Immunology and Their Application to Cancer Vaccines
Bullock, T. N. J. (2020) · Clinical and Translational Science · doi:10.1111/cts.12856 · Cited by 6
Knopick, P. L., Terman, D. S., Riha, N., Alvine, T., Larson, R., Badiou, C., Lina, G., Ballantyne, J. A., & Bradley, D. S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001493 · Cited by 6
Cai, L., Du, X., Zhang, C., Yu, S., Liu, L., Zhao, J., Zhao, Y., Zhang, C., Wu, J., Wang, B., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03095-z · Cited by 7
Zhou, L. Y., Zou, F., & Sun, W. (2022) · Biometrics · doi:10.1111/biom.13717 · Cited by 6
“Cancer vaccine studies have also shown that HLA-II neoantigens elicit CD4+ T cell response and confer strong antitumor activity (Kreiter et al., 2015; Ott et al., 2017; Sahin et al., 2017).”
BackgroundCancer vaccine strategies for the treatment of diffusely infiltrating gliomas
Jucht, A., Dumont, S. D., Pooley, C. S., & Castro, L. N. G. (2023) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/25151355231206163 · Cited by 6
Adding to the checkpoint blockade armamentarium
Hellmann, M. D., & Snyder, A. (2019) · Nature Medicine · doi:10.1038/s41591-019-0350-5 · Cited by 6
Sharif, E., Mobasheri, T., & Mohit, E. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127088 · Cited by 5
The interplay between the immune response and neoadjuvant therapy in breast cancer
Thomas, N., Foukakis, T., & Willard-Gallo, K. E. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1469982 · Cited by 5
Teffera, Z. H., Abebaw, D., Akelew, Y., Belayneh, M., Mesganaw, B., Selabat, B., Tefera, S., Belew, H., & Gedefaw, L. (2025) · Discover Viruses. · doi:10.1007/s44370-025-00019-8 · Cited by 5
“This approach allows the antigens to be expressed endogenously within the DCs, closely mimicking natural infection and leading to more efficient presentation on MHC class I molecules, which are critical for activating CTLs [77].”
Bao, L., Zhu, M., Luo, M., Kumar, A., Peng, Y., Xing, C., Wang, Y., & Luo, W. (2025) · Journal of Clinical Investigation · doi:10.1172/jci188801 · Cited by 5
Moorthy, T., Yalamandala, B. N., Huynh, T. M. H., Lien, H., Pan, W.-C., Iao, H. M., Chang, Y., & Hu, S. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01935-4 · Cited by 5
Lipid nanoparticle-assisted mRNA therapy for cancer treatment
Kim, H.-J., Le, N. D., Oh, H.-J., Kim, B., Yoo, E., Kim, J., & Yim, H. (2025) · Applied Physics Reviews · doi:10.1063/5.0247029 · Cited by 6
Immunologic specificity in glioblastoma: Antigen discovery and translational implications
Hill, C. M., Wang, A. Z., Hsueh, B., Ramirez, R., Sherpa, N. D., Costa, M. A., Williams, O., Mao, L., & Dunn, G. P. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf028 · Cited by 10
“279 Class II expression by tumor cells is associated with improved survival in many cancers.”
Zou, J., Meng, G., Huang, Y., Huo, J., Yuan, H., Ma, H., You, Z., Yan, X., Shen, B., Zhang, M., et al. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123901 · Cited by 5
Shen, K.-Y., Yu, S.-Z., Su, Y., Xie, S., Zhang, C., Xu, H., Yang, S., Zou, T., Fu, Y., Wang, H., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02511-5 · Cited by 5
“34,35 Therefore, more efforts are warranted to investigate whether the delivery of a broader spectrum and variety of neoantigens via oncolytic viruses can further improve therapeutic ef fi cacy.”
Pipe dream to pipeline: Journey of cancer vaccines and the road ahead
Onkar, S., Bozkus, C. C., Saxena, M., & Bhardwaj, N. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102575 · Cited by 7
Cancer Neoantigen Vaccines Emerge Efficacious
Sultan, H., & Schreiber, R. D. (2026) · Annual Review of Medicine · doi:10.1146/annurev-med-071723-045853 · Cited by 5
From Design to Clinical Use: mRNA Vaccines for Infectious Diseases and Cancer
Cui, Y., Liang, Z., & Hua, C. (2026) · Vaccines · doi:10.3390/vaccines14030202 · Cited by 6
“As our understanding of tumor-specific antigens deepens, cancer vaccine research is becoming an increasingly popular topic in the field, driving ongoing breakthroughs in personalized therapy and technological optimization [92,93].”
Han, J., Zhou, J., Dwivedy, A., Xue, T., Bhatta, R., Liu, Y., Nguyen, D., Yang, B., Wang, Y., Wang, X., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2504976123 · Cited by 5
“Among them, mRNA vaccines that encode tumor-specific neoantigens have emerged as a promising platform for clinical translation (15–18), especially in light of the tremendous success of mRNA vaccines in the era of COVID-19.”
Hos, B. J., Tondini, E., Camps, M. G. M., Rademaker, W., van den Bulk, J., Ruano, D., Janssen, G. M. C., de Ru, A. H., van den Elsen, P. J., de Miranda, N. F. C. C., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111680 · Cited by 6
Rath, S., Shafeea, M. S., Hussein, A. F. A., Hashim, A. S., Hassanaien, S., Pastrana-Brandes, S., & Chaurasia, B. K. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002491 · Cited by 7
“While the biological roles of most of these newly discovered candidate antigens in meningioma or other tumor types are not yet fully understood, a few, such as NMNA2 and WNT5A, are known to promote cancer cell survival [33] .”
BackgroundMHC class II-mediated spontaneous rejection of breast carcinomas expressing model neoantigens
Jenkins, J. W., Peña, A., Castro, S. A., Hansen, M. J., Keulen, V. P. V., Foster, S. T., Rios-Cruz, P. E., Yakubov, J., Hinson, D. T., Olivier, S. M., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010434 · Cited by 5
Biomaterials for cancer immunotherapy
Alhallak, K., Sun, J., Muz, B., & Azab, A. K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102983-1.00018-1 · Cited by 5
Stat5−/− CD4+ T cells elicit anti-melanoma effect by CD4+ T cell remolding and Notch1 activation
Jin, K., Li, T., Miao, Z., Ran, J., Chen, L., Mou, D., Wang, C., Wu, S., Yang, H., & Fu, X.-Y. (2022) · Science China Life Sciences · doi:10.1007/s11427-021-2078-6 · Cited by 7
“Accumulating evidence has indicated that tumor-specific CD4+ T cells in TILs exert outstanding antitumor immune effects in some tumor settings (Alspach et al., 2019; Borst et al., 2018; Kreiter et al., 2015; Oh et al., 2020; Śledzińska et al., 2020; Tran et al., 2014).”
BackgroundChen, Y., Zhao, H., Luo, J., Liao, Y., Dan, X., Hu, G., & Gu, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.944511 · Cited by 5
Oncolytic adenovirus coding for shedding-resistant MICA enhances immune responses against tumors
Costa-García, M., Rojas, J. J., Ramos, M., Barlabé, P., Calvo, P., Navas, J. J. J., Alemany, R., & Moreno, R. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03611-3 · Cited by 5
Neo-antigen specific T cell responses indicate the presence of metastases before imaging
Fear, V. S., Forbes, C. A., Chee, J., Ma, S., Neeve, S. A., Celliers, L., Fisher, S. A., Dick, I. M., Creaney, J., & Robinson, B. W. S. (2019) · Scientific Reports · doi:10.1038/s41598-019-51317-3 · Cited by 5
Muramatsu, T., Noguchi, T., Sugiyama, D., Kanada, Y., Fujimaki, K., Ito, S., Gotoh, M., & Nishikawa, H. (2020) · International Immunology · doi:10.1093/intimm/dxaa049 · Cited by 5
Harada, M., Iida, Y., Kotani, H., Minami, T., Komohara, Y., Eto, M., Yoshikawa, K., & Uemura, H. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02992-7 · Cited by 5
Servin-Garrido, R. R., Ilhuicatzi-Alvarado, D., Jiménez-Chávez, Á. D. J., & Moreno‐Fierros, L. (2022) · Breast Cancer Basic and Clinical Research · doi:10.1177/11782234211065154 · Cited by 5
Adoptive Cell Transfer and Vaccines in Melanoma: The Horizon Comes Into View
Warner, A. B., Sullivan, R. J., & Sarnaik, A. A. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351114 · Cited by 5
Zhao, J., Liao, B., Gong, L., Yang, H., Li, S., & Li, Y. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2254262 · Cited by 5
“46 Sipuleucel-T, a dendritic cell vaccine, and gp100, a peptide vaccine, were observed to have strong bursts of interest, highlighting their significant contributions to the field of therapeutic cancer vaccine research.”
BackgroundCancer vaccines: limited success but the research should remain viable
Baxevanis, C. N., & Perez, S. A. (2016) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1145057 · Cited by 5
“Furthermore, there is increasing evidence to suggest that neoantigens can also be presented to T cells in the context of major histocompatibility complex class II molecules [13].”
BackgroundThe dynamics of an immunotherapy duo
Shavkunov, A. S., & Gubin, M. M. (2022) · Nature Cancer · doi:10.1038/s43018-022-00362-5 · Cited by 5
Cross-competition shapes CD8+ T cell hierarchies and differentiation after RNA vaccinationPreprint
McCarron, M. J., Hornburg, M., Wu, T. D., Tong, A.-J., Tähtinen, S., Darwish, M., Freund, E. C., Feng, Y., Eisel, D., Balança, C.-C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.26.684631 · Cited by 6
Self-citationHLA class II-restricted T cell epitopes in public neoantigens of ESR1 and PIK3CA in breast cancer
Ando, Y., Miyadera, H., Bando, H., Hashimoto, S., Noguchi, E., & Hara, H. (2025) · BMC Cancer · doi:10.1186/s12885-025-13992-6 · Cited by 4
Properties of CD8 T-cell-recognized neoantigens in different tumor types
Ketelaars, S. L. C., van Buuren, M. M., Gangaev, A., van Rooij, N., Patiwael, S., Hoefakker, K., Fanchi, L. F., Baas, P., van der Heijden, M., Kok, M., et al. (2025) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2025.101062 · Cited by 4
“27,28 Nevertheless, the number of potentially immunogenic neoantigens is likely underestimated due to the restricted number of T cells available for analysis, (pre-) treatment effects or tumor-related immune suppression and TCR repertoire skewing.”
Song, X., Lu, C., Shi, T., Wang, H., Liu, W., Luo, Y., Zhou, X., Wang, Y., Ren, S., Yu, L., et al. (2025) · Med · doi:10.1016/j.medj.2025.100936 · Cited by 9
Ye, J., Zhao, Y., Zhang, B., Li, S., Li, J., Yu, J., Liu, H., & Wang, Y. (2026) · ACS Nano · doi:10.1021/acsnano.5c18030 · Cited by 4
Miyake-Stoner, S. J., Maine, C. J., Chou, A. C., Dailey, G. P., Spasova, D. S., Domingo, C. C., Sparks, J., Picarda, G. G. A., Lyerly, H. K., Crosby, E. J., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.03.026 · Cited by 4
Take Five: harmonization in personalized cancer vaccines for cancer immunotherapy
Cho, S., Lee, J., Lee, Y.-M., & Nam, J. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-026-01807-y · Cited by 4
A Necroptosis-Related Gene Signature to Predict the Prognosis of Skin Cutaneous Melanoma
Xie, Y., Xu, Z., Mei, X., & Shi, W. (2022) · Disease Markers · doi:10.1155/2022/8232024 · Cited by 4
“Mutations identified by exome sequencing can serve as vaccine targets solely through bioinformatics prioritization based on their expression levels and MHC class II-binding capacity for rapid production as synthetic poly-neo-epitope mRNA vaccines [49].”
BackgroundTransplantable Murine Tumors in the Studies of Peptide Antitumor Vaccines
Ponomarev, А. V., Shubina, I. Z., Za, S., Baryshnikova, M. A., & Kosorukov, V. S. (2024) · Oncology Reviews · doi:10.3389/or.2023.12189 · Cited by 4
“The results of a study of a therapeutic RNA vaccine including a mixture of fi ve neoantigenic peptides (pentatope 2) demonstrated a signi fi cant antitumor effect [25].”
BackgroundInfluentialMahmood, M., Taufiq, I., Mazhar, S., Hafeez, F., Malik, K. A., & Afzal, S. (2024) · Personalized Medicine · doi:10.1080/17410541.2024.2341610 · Cited by 6
Tian, C., Sun, X., Zhu, H., Zhou, M., Chen, Q., Min, D., Huang, Y. T., & Han, K. (2024) · Immunotherapy Advances · doi:10.1093/immadv/ltae010 · Cited by 4
“ELISPOT kits (BD Biosciences) were used to determine the amount of cytokine-secreting T cells after overnight activation with a peptide [19].”
Capturing and Tracking Clonal T-cell Response to Cancer Neoantigens
Shagina, I. A., Nakonechnaya, T. O., Izosimova, A. V., Shabalkina, A. V., Yuzhakova, D. V., Skatova, V. D., Lupyr, K. R., Muftakhutdinov, I., Izraelson, M., Davydov, A. N., et al. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-1216 · Cited by 4
Prakash, A., Mahoney, K. E., & Orsburn, B. C. (2021) · Cancers · doi:10.3390/cancers13153754 · Cited by 4
“An additional data analysis challenge is sequencing mutated peptides that are typically considered the best targets for cancer immunotherapy [2,3,18].”
BackgroundVaccine boosts T cells that target pancreatic tumours
Huff, A. L., & Zaidi, N. (2023) · Nature · doi:10.1038/d41586-023-01526-8 · Cited by 4
Homan, E. J., & Bremel, R. D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1155679 · Cited by 4
Morisaki, T., Kubo, M., Morisaki, S., Umebayashi, M., Tanaka, H., Koya, N., Nakagawa, S., Tsujimura, K., Yoshimura, S., Kiyotani, K., et al. (2024) · Cancers · doi:10.3390/cancers16244204 · Cited by 8
FcRn-guided antigen trafficking enhances cancer vaccine efficacy
Hong, M., Liu, M., Zhu, F., Zhao, D., Liu, G., Han, T., Fei, C., Zeng, W., Chen, S., Wu, Q., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03888-y · Cited by 4
Immunothérapie des tumeurs cérébrales
Carli, É. D., Delion, M., & Rousseau, A. (2017) · Annales de Pathologie · doi:10.1016/j.annpat.2016.12.001 · Cited by 5
Deumelandt, K., Platten, M., & Ochs, K. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox169 · Cited by 4
High-affinity T cell receptors for adoptive cell transfer
Isser, A., & Schneck, J. P. (2018) · Journal of Clinical Investigation · doi:10.1172/jci125471 · Cited by 4
Metadata
- Authors
- Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., Tadmor, A. D., Schoenberger, S. P., Huber, C., Türeci, Ö., & Sahin, U.
- Affiliations
- Johannes Gutenberg University Mainz (DE)
- La Jolla Institute for Immunology (US)
- ORCID
- Venue
- Nature
- Published
- 2015-04-22
- Volume
- 520
- Issue
- 7549
- Pages
- 692-696
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4838069
- OpenAlex
- W2079696222
- Cited by
- 1,243
- References
- 31
- Citations by year
- 2026: 64 · 2025: 93 · 2024: 114 · 2023: 120 · 2022: 124 · 2021: 149 · 2020: 144 · 2019: 101 · 2018: 99 · 2017: 99 · 2016: 95 · 2015: 38
- FWCI
- 54.27
- Type
- journal article
- Language
- en
- Update notices
- erratum (2015-06-03)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI107010)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- tumour mutations, MHC class II epitopes, neoantigens, CD4+ T cells, mRNA vaccines, personalized cancer immunotherapy, MHC class II binding prediction, tumor microenvironment, cytotoxic T lymphocytes, tumor rejection, exome sequencing, tumor immunogenicity
- MeSH terms
- Algorithms, Animals, Histocompatibility Antigens Class II, Computer Simulation, Disease Models, Animal, Female, Humans, Immunotherapy, Melanoma, Experimental, Mutation, CD4-Positive T-Lymphocytes, Survival Analysis, Sequence Analysis, DNA, Epitopes, T-Lymphocyte, Cancer Vaccines, Mice, Precision Medicine, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.